Under the terms of the agreement, BC Tech will be responsible for manufacturing the MedClose system for use in commercial applications to seal the femoral artery access site following cardiac and peripheral vascular catheterization procedures when approved. BC Tech will also build prototypes of larger caliber for potential use in percutaneous procedures. Initially, BC Tech will manufacture MedClose systems on a limited basis and does not expect to commence large scale manufacturing until the Company has obtained commercial application approvals.
With a state-of-the-art design and manufacturing facility in
"This agreement with BC Tech is a critical step toward bringing
MedClose(TM) to market," said
"We are pleased to help bring innovative solutions like MedClose(TM) to
patients and the medical community," said
About CPC
CPC of America acquires, develops and oversees the manufacturing of therapeutic devices for use in endovascular procedures. CPC's current focus is the completion of development and testing of the MedClose(TM) vascular closure system, an internal puncture-closing system for use in catheter laboratories.
About BC Tech
BC Tech is a full-service medical and biotech company that offers complete research, development, manufacturing and support services for Class I, II, and III medical devices, disposables, and lab automation equipment. Over the last 15 years, BC Tech has completed more than a hundred projects for satisfied customers around the world.
Forward Looking Statements
The statements contained in this press release that are not historical are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
including statements, without limitation, regarding the Company's
expectations, beliefs, intentions or strategies regarding the future. Such
forward-looking statements relate to, among other things: (1) the Company's
continuing development of its MedClose(TM) vascular closure system, (2) the
Company's expectations concerning regulatory approvals of the MedClose system
and the commencement of revenue producing operations based on the sale or
licensing of the MedClose, (3) the business relationship between the Company
and BC Tech and the expected benefits to the Company from such relationship,
and (4) the commencement of manufacturing of the MedClose system. These
statements are qualified by important factors that could cause the Company's
actual results to differ materially from those reflected by the forward-
looking statements. Such factors include but are not limited to: (1) the
Company's ability to finance the continued development and commencement of
manufacturing of the MedClose system, (2) Regulatory approvals of the
MedClose system, (3) the general risks and uncertainties inherent in any new
business relationship such as the one recently entered into between the
Company and BC Tech, and (4) those other risks and factors described from time
to time in the Company's reports filed with the Securities and Exchange
Commission, including but not limited to the Company's Annual Report on Form
10-K for the year ended
SOURCE CPC of America, Inc.